Plain-English translation of NCT07251491 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing psilocybin — a naturally occurring compound from certain mushrooms — as a potential treatment for depression in veterans with spinal cord injuries. Depression is very common in people with spinal cord injuries, and current treatments don't work well for everyone. Researchers want to see if this medication might help reduce depression symptoms and improve quality of life.
Many people with spinal cord injuries struggle with depression that doesn't respond well to standard antidepressants. Early research suggests this medication may help people with depression by changing how the brain processes certain chemicals, but it has never been properly tested in people with spinal cord injuries.
You likely qualify if…
You likely don't qualify if…
You would come to at least 16 study visits over about a year. At the main visit, you would take the medication in a controlled medical setting with trained therapists present to support you. Between visits, you would have follow-up appointments where doctors check your mood, pain levels, side effects, and overall wellbeing. You would not know which dose of the medication you received, and all visits would be recorded with audio and video for safety and research purposes.
AI-generated summary from trial data · Aug 17, 2026 · Not medical advice
United States